Emerald Health Therapeutics (EMHTF) Return on Assets ROA from the fourth quarter of 2019 to fourth quarter of 2018 and for the year 2019, Average High and Low, Fundamental Ratios from Dec 31 2019 to Dec 31 2018 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Emerald Health Therapeutics Inc.  (EMHTF)


Emerald Health Therapeutics's ROA from the fourth quarter of 2019 to the fourth quarter of 2018 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Emerald Health Therapeutics's ROA in the fourth quarter of 2019?
Emerald Health Therapeutics Inc. achieved a return on average assets (ROA) of 57.9 % in its fourth quarter of 2019, this is above EMHTF's average return on assets of 36.41%.
Emerald Health Therapeutics Inc. assets over the 12 months ending in its fourth quarter of 2019 are valued at $120 million

ROA has improved compared to 5.73% in the third quarter of 2019, due to net income growth.

However, within the Healthcare sector 17 other companies had a higher return on assets. While the total ranking for ROA unchanged, relative to the third quarter of 2019 at no. .

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Dec 31 2019)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2018)
IV. Quarter
Y / Y Total Assets Change -24.38 % -24.38 % -24.38 % -24.38 % -
Y / Y Net Income Change 261.18 % - - - -
Net Income (TTM) in million 69 7 16 12 10
Return On Assets (TTM) 57.9 % 5.73 % 11.3 % 7.88 % 6.61 %
EMHTF's Total Ranking # # # # 443 #
Total Assets (TTM) in million 120 120 120 120 159
Seq. Total Assets Change 0 % 0 % 0 % -24.38 % 0 %
Seq. Net Income Change - - - - -

EMHTF's 5 Years Annual ROA >> Back to EMHTF Management Effectiveness >> Compare EMHTF ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 10
Sector # 18
Overall # 89

Return On Assets Statistics
High Average Low
57.86 %
36.41 %
14.97 %
(Dec 31 2019)   (Dec 31 2018)





Financial Statements
Emerald Health Therapeutics's Assets $ 120 million EMHTF's Balance sheet
Emerald Health Therapeutics's Income $ 86 million Quarterly EMHTF's Income Statement
EMHTF's Income by Division See EMHTF's Income by Division



Annual Return On Assets (Dec 31 2019)
FY 2019		 (Dec 31 2018)
FY 2018
FY
FY
FY
Y / Y Total Assets Change -24.38 % - - - -
Total Assets in million 120 159 0 0 0
Y / Y Net Income Change 261.18 % - - - -
Net Income in million 86 24 0 0 0
Annual Return On Assets 71.5 % 14.97 % - - -

EMHTF's 5 Years Annual ROA >> Back to EMHTF Management Effectiveness >> Compare EMHTF ROA to its Competitors



Comment on EMHTF's ROA in the fiscal year ending 2019
In the fiscal year 2019 ROA improved to 71.5 % compared to prior year, due to annual net income growth of 261.18 % to $85.72 million, and due to decline of value in Emerald Health Therapeutics's assets by -24.38 % to $119.89 million, compared to $119.89 a year before.


More Return On Assets Ratios
EMHTF's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
EMHTF's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for EMHTF's Competitors
Subscribers only: Roa for Emerald Health Therapeutics's Suppliers
Subscribers only: Return On Assets for EMHTF's Customers

You may also want to know
EMHTF's Roi EMHTF's Inventory Turnover Ratio EMHTF's Growth Rates EMHTF's Dividend Comparisons
EMHTF's Profitability Ratios EMHTF's Asset Turnover Ratio EMHTF's Dividend Growth
EMHTF's Roe EMHTF's Valuation Ratios EMHTF's Financial Strength Ratios EMHTF's Dividend Payout Ratio



Companies with similar Return On Assets at Dec 31 2019, within Healthcare Sector ROA
Tuhura Biosciences Inc   142.02 %
Check Cap Ltd  125.11 %
Semler Scientific inc   107.70 %
Collplant Biotechnologies Ltd  103.83 %
Allarity Therapeutics Inc   100.30 %
Tenax Therapeutics Inc   95.23 %
Quoin Pharmaceuticals Ltd   78.83 %
Emerald Health Therapeutics Inc.  57.86 %
Redhill Biopharma Ltd   57.09 %
Jounce Therapeutics inc   54.66 %
Molecular Templates Inc   51.51 %
Biovie Inc   51.11 %
REGENEREX PHARMA, INC.  47.34 %
Palatin Technologies Inc   46.45 %
Cnbx Pharmaceuticals Inc   46.39 %
Morphic Holding inc   44.08 %
Zynex inc   40.52 %
Lexicon Pharmaceuticals Inc   38.45 %
Purple Biotech Ltd  38.43 %
Ligand Pharmaceuticals Incorporated  37.25 %
Catalyst Pharmaceuticals Inc   36.60 %
Progyny Inc   35.30 %
Opiant Pharmaceuticals Inc   33.91 %
Oramed Pharmaceuticals Inc  33.91 %
Arena Pharmaceuticals Inc   31.61 %
Coherus Oncology inc   30.90 %
Orgenesis Inc   30.51 %
Nrc Health  30.34 %
Innoviva Inc   29.01 %
Vanda Pharmaceuticals Inc   27.48 %

Date modified: 2026-08-30T12:48:15+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.